Analytical Data
-
Gene name
VENTX
- Application
-
Alternative Names
May be involved in ventralization.
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95231
-
Expression Region
1-258aa
-
Molecular Weight
54.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VENTX is a groundbreaking recombinant protein developed for various applications in biochemistry and molecular biology. Its research background stems from the increasing need for efficient and effective therapeutic agents, particularly in the fields of protein engineering and synthetic biology. Traditional methods of producing proteins often fall short in terms of yield, purity, and functionality. VENTX addresses these challenges by utilizing advanced expression systems that enhance the quality and activity of the protein. This recombinant protein promises to facilitate significant advancements in drug development, diagnostics, and therapeutic interventions. By optimizing its production through innovative techniques, researchers aim to explore VENTX’s potential in targeting specific biological pathways, thus paving the way for novel treatments for diseases. The versatility of VENTX not only broadens the scope of research but also holds promise for transforming clinical practices. As scientists continue to investigate its properties, VENTX is positioned at the forefront of protein research, embodying the intersection of biotechnology and healthcare innovation.
